SPARC enters licensing pact with Biomodifying for licensing of novel drug targets against cancer

“This is an important milestone for SPARC. The licensing of antibodies from Biomodifying will assist us in our endeavour to transition SPARC into a company focussed on novel treatment modalities, including bi-specific antibodies and antibody drug conjugates" said Anil Raghavan, CEO of SPARC.

from Healthcare/Biotech-Industry-Economic Times https://ift.tt/3lwfHzM
via IFTTT